2021
DOI: 10.1016/j.eimc.2020.02.016
|View full text |Cite
|
Sign up to set email alerts
|

Epidemiology of pneumococcal diseases in Spain after the introduction of pneumococcal conjugate vaccines

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

0
3
0
1

Year Published

2021
2021
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 10 publications
(4 citation statements)
references
References 56 publications
0
3
0
1
Order By: Relevance
“…Globally, S. pneumoniae causes over 800,000 deaths in children and 13.8 million cases of pneumonia each year. Different vaccines have been generated against the most prevalent S. pneumoniae serotypes, of which the conjugate 13-valent (PCV13) and the polysaccharide-based 23-valent (PCV23) are often used ( 4 ). The use of antibiotics is becoming compromised by the ever-increasing appearance of antibiotic-resistant strains ( 5 7 ).…”
Section: Introductionmentioning
confidence: 99%
“…Globally, S. pneumoniae causes over 800,000 deaths in children and 13.8 million cases of pneumonia each year. Different vaccines have been generated against the most prevalent S. pneumoniae serotypes, of which the conjugate 13-valent (PCV13) and the polysaccharide-based 23-valent (PCV23) are often used ( 4 ). The use of antibiotics is becoming compromised by the ever-increasing appearance of antibiotic-resistant strains ( 5 7 ).…”
Section: Introductionmentioning
confidence: 99%
“…Un aumento del número total de casos notificados de ENI se ha observado también en Cataluña comparando los periodos 2010-2014 y 2017-2018 24 , 25 . Aunque esta tendencia ascendente en los casos totales de ENI está sin duda influenciada por algunos cambios introducidos en el sistema de notificaciones (la ENI es enfermedad de declaración obligatoria desde 2015), no puede descartarse un agotamiento del potencial impacto actual de los programas de vacunación con las actuales formulaciones VNC13 y VNP23 26 , 27 , 28 .…”
Section: Discussionunclassified
“…As it already happened in multicenter studies carried out in our country and at a European level, a significant reduction in IPD caused by serotypes included in PCV-13 has been seen. It should be noted that this effect has been magnified in communities that had included the universal childhood vaccination program earlier [ 26 ]. Another reason could be cross immunity as observed against serotypes not included in PCV-10 before the implementation of PCV-13, with a decrease in the incidence of serotype 19A (which is not included in PCV-10) [ 27 , 28 ].…”
Section: Discussionmentioning
confidence: 99%